{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:42:30Z","timestamp":1782805350029,"version":"3.54.5"},"reference-count":24,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hallym University Research Fund 2021","award":["HURF-2021-21"],"award-info":[{"award-number":["HURF-2021-21"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The receptor for advanced glycation end-products (RAGE) may serve as a diagnostic and prognostic biomarker of lung cancer and lung injury. We explored whether the serum and bronchial levels of soluble RAGE (sRAGE) distinguished infectious lung diseases from lung cancer. We collected serum and bronchial washing fluids (BWFs) from patients diagnosed with pneumonia, tuberculosis, or preoperative lung cancer from April 2016 to March 2022. sRAGE levels were measured using an enzyme-linked immunosorbent assay and we drew receiver operating characteristic (1) curves to determine the cut-off values affording the best diagnostic sensitivities. We enrolled 81 patients including 20 with tuberculosis, 30 with pneumonia, and 31 with lung cancer. Of the 81, 61% were males and the median age was 66 years. The median serum level of sRAGE was 822 (678\u20131168 pg\/mL) and did not differ significantly between the three groups. The median bronchial sRAGE level was 167 (83\u2013529 pg\/mL) but 231 (108\u2013649 pg\/mL) for tuberculosis, 366 (106\u2013706 pg\/mL) for pneumonia, and 103 (32\u2013254 pg\/mL) for lung cancer patients (p = 0.018). The ROC curve for the bronchial sRAGE values of lung cancer patients revealed that the optimal cut-off was 118.9 pg\/mL. This afforded a sensitivity of 76%, a specificity of 58%, and an area under the ROC curve of 0.695 (p = 0.005). The level of bronchial sRAGE differed significantly between patients with lung cancer and other respiratory diseases; that level may serve as an auxiliary diagnostic biomarker.<\/jats:p>","DOI":"10.3390\/cancers15102819","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:03:58Z","timestamp":1684393438000},"page":"2819","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Diagnostic Utility and Tendency of Bronchial and Serum Soluble Receptor for Advanced Glycation EndProducts (sRAGE) in Lung Cancer"],"prefix":"10.3390","volume":"15","author":[{"given":"Taehee","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul 07440, Republic of Korea"},{"name":"Lung Research Institute, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9141-7749","authenticated-orcid":false,"given":"Soo Jung","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul 07440, Republic of Korea"},{"name":"Lung Research Institute, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-0653","authenticated-orcid":false,"given":"Hayoung","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul 07440, Republic of Korea"},{"name":"Lung Research Institute, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Rim","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul 07440, Republic of Korea"},{"name":"Lung Research Institute, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3746-4947","authenticated-orcid":false,"given":"Yun Su","family":"Sim","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul 07440, Republic of Korea"},{"name":"Lung Research Institute, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"917108","DOI":"10.1155\/2010\/917108","article-title":"The receptor for advanced glycation end products (RAGE) and the lung","volume":"2010","author":"Buckley","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0169-409X(02)00160-6","article-title":"Receptor for advanced glycation endproducts: A multiligand receptor magnifying cell stress in diverse pathologic settings","volume":"54","author":"Stern","year":"2002","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1096\/fj.08-109033","article-title":"A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)","volume":"22","author":"Raucci","year":"2008","journal-title":"FASEB J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/thx.2008.095588","article-title":"Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury","volume":"63","author":"Calfee","year":"2008","journal-title":"Thorax"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1164\/rccm.201501-0020OC","article-title":"Soluble Receptor for Advanced Glycation End-Products Predicts Impaired Alveolar Fluid Clearance in Acute Respiratory Distress Syndrome","volume":"192","author":"Jabaudon","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1089\/rej.2014.1625","article-title":"Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk","volume":"18","author":"Yamagishi","year":"2015","journal-title":"Rejuvenation Res."},{"key":"ref_7","first-page":"445","article-title":"Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer","volume":"10","author":"Kuniyasu","year":"2003","journal-title":"Oncol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2559.2007.02739.x","article-title":"Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma","volume":"51","author":"Sasahira","year":"2007","journal-title":"Histopathology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/07357900701560521","article-title":"Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer","volume":"25","author":"Tesarova","year":"2007","journal-title":"Cancer Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4149\/neo_2010_01_055","article-title":"Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): A new biomarker for lung cancer","volume":"57","author":"Jing","year":"2010","journal-title":"Neoplasma"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Peng, Y., Liu, F., Qiao, Y., Wang, P., Du, H., Si, C., Wang, X., Chen, K., and Song, F. (2022). Genetically Modified Circulating Levels of Advanced Glycation End-Products and Their Soluble Receptor (AGEs-RAGE Axis) with Risk and Mortality of Breast Cancer. Cancers, 14.","DOI":"10.3390\/cancers14246124"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/carcin\/bgh333","article-title":"Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma","volume":"26","author":"Bartling","year":"2005","journal-title":"Carcinogenesis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"697","DOI":"10.47162\/RJME.62.3.06","article-title":"Lung cancer mimickers-a case series of seven patients and review of the literature","volume":"62","author":"Neacsu","year":"2021","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CPM.0b013e31827a30c1","article-title":"Risks of Transthoracic Needle Biopsy: How High?","volume":"20","author":"Wiener","year":"2013","journal-title":"Clin. Pulm. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jtcvs.2017.08.138","article-title":"The eighth edition TNM stage classification for lung cancer: What does it mean on main street?","volume":"155","author":"Detterbeck","year":"2018","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_17","first-page":"147","article-title":"Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases","volume":"9","author":"Kamo","year":"2015","journal-title":"Clin. Med. Insights Circ. Respir. Pulm. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"da Silva, L.F., Skupien, E.C., Lazzari, T.K., Holler, S.R., de Almeida, E.G.C., Zampieri, L.R., Coutinho, S.E., Andrades, M., and Silva, D.R. (2019). Advanced glycation end products (AGE) and receptor for AGE (RAGE) in patients with active tuberculosis, and their relationship between food intake and nutritional status. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0213991"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.semcancer.2017.07.001","article-title":"AGEs, RAGEs and s-RAGE; friend or foe for cancer","volume":"49","author":"Ahmad","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3818196","DOI":"10.1155\/2020\/3818196","article-title":"Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects","volume":"2020","author":"Perrone","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101958","DOI":"10.1016\/j.redox.2021.101958","article-title":"The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes","volume":"42","author":"Erusalimsky","year":"2021","journal-title":"Redox Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/35012626","article-title":"Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases","volume":"405","author":"Taguchi","year":"2000","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"112030","DOI":"10.1016\/j.yexcr.2020.112030","article-title":"The receptor for advanced glycation end-products enhances lung epithelial wound repair: An in vitro study","volume":"391","author":"Zhai","year":"2020","journal-title":"Exp. Cell Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/ckj\/sfaa188","article-title":"External validation of prognostic models: What, why, how, when and where?","volume":"14","author":"Ramspek","year":"2021","journal-title":"Clin. Kidney J."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/10\/2819\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:37:43Z","timestamp":1760125063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/10\/2819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["cancers15102819"],"URL":"https:\/\/doi.org\/10.3390\/cancers15102819","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]}}}